Karolinska Development appoints new CEO
15 October 2014
Swedish medical technology company Karolinska Development
has announced that Bruno Lucidi has been appointed as permanent CEO
from today, in addition to existing positions in the company.
“We are happy to welcome Bruno Lucidi as permanent CEO”, says
Karolinska Development’s Chairman Bo Jesper Hansen. “As communicated
on September 30, 2014, we need a new strategy and a new leadership
to realize the true potential of Karolinska Development and its
portfolio companies. We are convinced that Bruno has the right
skills and experiences to lead the company during this important
phase where a more effective and compelling strategy for the future
needs to be executed”.
Bruno Lucidi has extensive international experience in the
pharmaceutical, biotechnology and financial industry. In his
previous positions as founding CEO of Idenix and Chairman of
Pharmasset, he has contributed to maturing the companies to a level
that eventually resulted in both companies being acquired by
multinational pharmaceutical companies.
He has also held senior positions within Bristol-Myers Squibb,
Johnson & Johnson and at GlaxoSmithKline. Since September 8, 2014,
Bruno Lucidi has been CEO of the Karolinska Development’s wholly
owned subsidiary KDev Oncology as well as of the portfolio companies
Aprea and Akinion. He will keep these positions and will assume his
new role as CEO of Karolinska Development.
“I am very pleased to take up this position and look forward to
taking Karolinska Development to the next stage in its development”,
says CEO Bruno Lucidi. “There are several opportunities to have
major positive impact on patients’ lives in our portfolio companies
and this represent certainly significant business opportunities. I
am definitely convinced that Karolinska Development with its new
strategy will be able to unlock these values”.
Bruno Lucidi will assume his new position and take over from
acting CEO Klaus Wilgenbus with immediate effect on October 15,
2014. This means that Bruno Lucidi will present Karolinska
Development´s new strategy on its Capital Markets Day in Solna,
Stockholm, on October 21, 2014. Klaus Wilgenbus will continue as a
consultant to the Board and Management until the end of the year.
“The board would like to thank Klaus Wilgenbus for making himself
available immediately and taking the role as acting CEO of the
company during this short but critical period when we were searching
for a permanent solution”, says Bo Jesper Hansen.
Source: Karolinska Development press release.